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Abstract: Bufalin is a class of toxic steroids which could induce the differentiation and 
apoptosis of leukemia cells, and induce the apoptosis of gastric, colon and breast cancer 
cells. However, the anti-tumor effects of bufalin have not been demonstrated in lung cancer. 
In this study we used A549 human lung adenocarcinoma epithelial cell line as the 
experimental model to evaluate the potential of bufalin in lung cancer chemotherapy. A549 
cells were treated with bufalin, then the proliferation was detected by MTT assay and 
apoptosis was detected by flow cytometry analysis and Giemsa staining. In addition, A549 
cells were treated by Akt inhibitor LY294002 in combination with bufalin and the 
activation of Akt and Caspase-3 as well as the expression levels of Bax, Bcl-2 and livin 
were examined by Western blot analysis. The results showed that Bufalin inhibited the 
proliferation of A549 cells and induced the apoptosis of A549 cells in a dose and time 
dependent manner. Mechanistically, we found that bufalin inhibited the activation of Akt. 
Moreover, bufalin synergized with Akt inhibitor to induce the apoptosis of A549 cells and 
this was associated with the upregulation of Bax expression, the downregulation of Bcl-2 
and livin expression, and the activation of Caspase-3. In conclusion, our findings 
demonstrate that bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt 
pathway and suggest that bufalin is a potential regimen for combined chemotherapy to 
overcome the resistance of lung cancer cells to chemotherapeutics induced apoptosis. 
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1. Introduction 
Lung cancer is one of the most common malignant tumors. Non-small cell lung cancer (NSCLC) 
accounts for nearly 85% of all lung cancer cases and the majority of them are diagnosed at advanced 
stages. The 5-year survival rate of NSCLC patients has only been increased to 15% despite recent 
development in chemotherapy [1]. Current chemotherapy protocols for NSCLC mainly include the 
combination of classic drugs, such as cisplatin or carboplatin, with new drugs, such as gemcitabine, 
vinorelbine, paclitaxel, or docetaxel [2,3]. However, these drugs for NSCLC are known to induce 
chemoresistance and have a range of side effects such as hair loss, nerve damage, hearing loss, kidney 
damage, or allergic reactions. Therefore, it is urgent to develop novel chemotherapies that are highly 
effective and less toxic.   
Bufalin is a class of toxic steroids purified from Chinese traditional medicine chan'su. Recent 
studies have shown that bufalin exhibits anti-tumor effects [4,5]. Bufalin could induce the differentiation 
and apoptosis of leukemia K562 and HL-60 cells, and induce the apoptosis of gastric cancer cells, 
colon cancer cells and breast cancer cells [6,7]. However, the anti-tumor effects of bufalin have not 
been demonstrated in lung cancer. 
Resistance to apoptosis is an important hallmark of tumor cells [8]. Apoptosis of tumor cells is 
known to be regulated by a variety of signaling pathways such as PI3k/Akt pathway. Akt has been 
shown to regulate apoptosis related proteins such as Bcl-2, Bax and caspase-3 and is crucially involved 
in anticancer drug induced apoptosis of cancer cells [9–12]. 
Based on previous reports, we hypothesized that bufalin could induce the apoptosis of lung cancer 
cells via the regulation of PI3K/Akt pathway. In this study we used A549 human lung adenocarcinoma 
epithelial cell line as the experimental model to test our hypothesis. Our results showed that bufalin 
could modulate the expression of apoptosis related proteins and induce the apoptosis of A549 cells, 
suggesting its potential application in lung cancer chemotherapy.   
2. Results and Discussion 
2.1. Bufalin Inhibits the Proliferation and Induces the Apoptosis of A549 Cells 
To investigate the effects of bufalin on A549 cells, we tested the effect of various doses of bufalin 
on the viability of A549 cells using MTT assay. The cells were treated for 48 h, 72 h, or 96 h.  
as shown in Figure 1a, cell growth was inhibited by bufalin in a dose and time dependent manner. IC50 
was calculated as 56.14 ± 6.72, 15.57 ± 4.28, and 7.39 ± 4.16 nmol/L for cells treated at 48 h, 72 h and   
96 h, respectively.   
We speculated that the reduced viability of A549 cells may be caused by the induction of apoptosis, 
thus we carried out PI/flow cytometry analysis to examine the apoptosis. A549 cells were treated with 
20 nmol/L, 40 nmol/L, or 100 nmol/L bufalin for 48 h or 72 h. Flow cytometry analysis showed that 
bufalin induced the apoptosis of A549 cells in a dose and time dependent manner (Figure 1b). Int. J. Mol. Sci. 2012, 13 2027 
 
 
Qualification of the apoptosis rate showed that the differences in apoptosis rate between control cells 
and cells treated with bufalin were significant (p < 0.01, Figure 1c). 
Figure 1. Bufalin inhibits the proliferation and induces the apoptosis of A549 cells. 
(a)  A549 cells were treated with 10 nmol/L, 20 nmol/L, 50 nmol/L, 100 nmol/L or 
200 nmol/L bufalin for 48 h, 72 h, or 96 h. The cell viability was examined by MTT assay. 
Data were derived from three independent experiments. (b) A549 cells were treated with 
20 nmol/L, 40 nmol/L, or 100 nmol/L bufalin for 48 h or 72 h. The apoptosis was 
examined by PI staining and flow cytometry analysis. (c) Quantification of apoptosis of 
A549 cells shown in (b). Data were derived from three independent experiments.* P < 0.01 
vs. control. 
 
To confirm that bufalin induces the morphology of apoptosis in A549 cells, we treated A549 cells 
with 100 nmol/L bufalin for 48 h and then performed Giemsa staining. The apoptotic morphology was 
obviously observed in bufalin treated cells under a microscope at 200× magnification, including 
cytoplasmic shrinkage, nuclear condensation and the formation of apoptotic bodies (Figure 2). 
However, no apoptotic morphology was observed in control treated cells. 
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Figure 2. Apoptotic morphology of A549 cells treated with bufalin. A549 cells were 
treated with vehicle (a) or 100 nmol/L bufalin (b) for 48 h and stained by Giemsa staining. 
cytoplasmic shrinkage, nuclear condensation and the formation of apoptotic bodies were 
observed in (b). Shown are representative images of three independent experiments. Scale 
bar: 40 μm. 
 
2.2. Bufalin Regulates the Expression of Apoptosis Related Proteins in A549 Cells 
Next we explored the molecular mechanism by which bufalin induces the apoptosis of A549 cells. 
A549 cells were treated with 100 nmol/L bufalin for 12 h, 24 h or 48 h and subjected to Western blot 
analysis. The results showed that bufalin increased Bax expression while decreased Bcl-2 expression at 
protein level in a time dependent manner (Figure 3a). Compared to control, the Bax/Bcl-2 ratio was 
1.27, 1.73, and 2.68 at 12 h, 24 h and 48 h，respectively (P < 0.05, P < 0.01, P < 0.01, respectively).   
In addition, we found that livin expression level was reduced to 61.29 ± 7.76%, 29.03 ± 4.63% and 
22.17 ± 6.02% of the control at 12 h, 24 h and 48 h, respectively (P < 0.01, Figure 3b). These results were 
expected because Bax is apoptosis promoting protein while Bcl-2 and livin are anti-apoptosis proteins. 
Furthermore, we examined the activation of apoptosis effector Caspase-3 by detecting the cleaved 
form of Caspase-3. With the prolongation of bufalin treatment, the amount of cleaved form of 
Caspase-3 (17 KD) increased (Figure 3c). To confirm that bufalin regulates the activation of Caspase-3, 
we employed Z-DEVD-fmk, a specific inhibitor of Caspase-3, and found that it could inhibit bufalin 
induced apoptosis of A549 cells (Figure 3d). Taken together, these results suggest that bufalin regulates 
the expression of apoptosis related proteins and the activation of Caspase-3 to induce the apoptosis of 
A549 cells. 
2.3. Bufalin Modulates the Activation of PI3K/Akt Pathway in A549 Cells 
To test our hypothesis that bufalin could induce the apoptosis of lung cancer cells via the regulation 
of PI3K/Akt pathway, first we detected the activation of Akt in A549 cells treated with 100 nmol/L 
bufalin. Western blot analysis showed that the level of p-Akt was reduced in bufalin treated cells 
compared to control cells, although the total level of Akt remained the same (Figure 4a). These results 
indicate that bufalin inhibits the activation of Akt in A549 cells. To provide further evidence, we 
employed specific Akt inhibitor LY2942002. Pretreatment with 25 μmol/L LY294002 for 2 h could 
significantly augment the inhibitory effects of bufalin on Akt activation (Figure 4a). Int. J. Mol. Sci. 2012, 13 2029 
 
 
Figure 3. Bufalin regulates the expression of apoptosis related proteins in A549 cells. 
(a)  Western blot analysis of Bcl-2 ad Bax protein level in A549 cells treated with 
100 nmol/L bufalin for different time. (b) Western blot analysis of livin protein level in 
A549 cells treated with 100 nmol/L bufalin for different time. (c) Western blot analysis of 
the levels of pro-caspase-3 and activated Caspase-3 in A549 cells treated with 100 nmol/L 
bufalin for different time: 1. 0 h; 2. 12 h; 3. 24 h; 4. 48 h. β-actin served as loading control. 
Shown are representative blots from three independent experiments with similar results. 
(d). A549 cells were treated with vehicle, 100 nmol/L bufalin alone or plus Z-DEVD-fmk 
and the apoptosis was examined by PI staining and flow cytometry analysis. Data were 
derived from three independent experiments.* P <0.01 vs. bufalin alone; * P <0.01 
vs. control. 
 
In addition, we found that pretreatment with LY294002 (25 μmol/L) could synergize with bufalin 
treatment (100 nmol/L) to induce the apoptosis of A549 cells as assessed by flow cytometry analysis 
(Figure 4b). Moreover, we examined the synergistic effects of Akt inhibitor and bufalin on the 
expression of apoptosis related proteins and the activation of Caspase-3. Western blot analysis 
demonstrated that LY294002 pretreatment (25 μmol/L for 2 h) could synergize with bufalin treatment 
(100 nmol/L for 48 h) to upregulate Bax expression, downregulate Bcl-2 and livin expression, and 
promote the activation of Caspase-3 (Figure 4c). These results suggest that bufalin could inhibit the 
activation of PI3k/Akt pathway to induce the apoptosis of A549 cells. Int. J. Mol. Sci. 2012, 13 2030 
 
 
Figure 4. Bufalin modulates the activation of PI3K/Akt pathway in A549 cells. 
(a) Western blot analysis of the level of p-Akt in differently treated A549 cells. Total Akt 
level served as loading control. Shown are representative blots from three independent 
experiments with similar results: 1. 0 h; 2. 100 nmol/L bufalin for 24 h; 3. 100 nmol/L 
bufalin for 48 h; 4. 25 μmol/L LY294002 for 2 h plus 100 nmol/L bufalin for 24 h; 5.  
25  μmol/L LY294002 for 2 h plus 100 nmol/L bufalin for 48 h. (b) A549 cells were 
pretreated with 25 μmol/L LY294002 for 2 h followed by treatment with 100 nmol/L 
bufalin for 48 h as indicated and the apoptosis was examined by PI staining and flow 
cytometry analysis. Data were derived from three independent experiments. * P < 0.01 vs. 
left three groups of cells. (c) Western blot analysis of the levels of Bcl-2, Bax, livin and 
activated caspase-3 in differently treated A549 cells. Total Akt served as loading control. 
Shown are representative blots from three independent experiments with similar results: 1. 
0 h; 2. 100 nmol/L bufalin for 24 h; 3. 25 μmol/L LY294002 for 2 h; 4. 25 μmol/L 
LY294002 for 2 h plus 100 nmol/L bufalin for 24 h. 
 
3. Materials and Methods 
3.1. Reagents and Antibodies 
Bufalin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was dissolved in ethyl 
alcohol to make 0.01 mol/L stock solution, which was kept at −20 °C and diluted in phosphate buffer 
saline (PBS) when used. LY294002 was purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
was dissolved in DMSO to make 0.01 mol/L stock solution, which was kept at 4 °C. Mouse antibodies Int. J. Mol. Sci. 2012, 13 2031 
 
 
specific for Caspase-3, Bcl-2, livin, p-Akt, Akt, and β-actin were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated goat anti-mouse secondary 
antibodies were obtained from Santa Cruz Biotechnology.   
3.2. Cell Culture 
A549 human lung adenocarcinoma epithelial cell line was obtained from Cell Bank of Shanghai 
Institute of Biochemistry & Cell Biology, Chinese Academy of Sciences (Shanghai, China), where 
they were tested and authenticated based on cross species checks, DNA authentication and quarantine. 
A549 cells were cultured at 37 °C with 5% CO2 in an air atmosphere in F12K medium (Sigma), 
supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin. A549 cells at 
exponential growth stage were employed in all of the experiments. 
3.3. MTT Assay   
MTT assay was employed to examine the effects of bufalin on the proliferation of A549 cells. 
Briefly, the cells were seeded in 96-well plates at 5 × 10
3 cells/well in 180 μL medium and cultured for 
12 h to allow attachment. Then the cells in the wells were treated with fresh medium containing 
different concentrations of bufalin diluted from stock solution. PBS was added to the wells as negative 
control. The cells were cultured for 48 h, 72 h, or 96 h. Four hours before the end of culture, MTT 
solution (5 mg/mL in 20 μL PBS) was added to each well and incubated for 4 h at 37 °C. The growth 
medium was then removed and replaced with DMSO (200 μL/well), and incubated for 10 min.  
A MR7000 microplate reader (Dynatech) was used to measure the absorbance of each well at 570 nm 
and IC50 values were calculated using the probit model. The inhibition rate of cell proliferation was 
calculated as follows: inhibition rate (%) = 1 − A570 (test)/A570 (control) × 100%. Data were calculated 
from three independent experiments, each performed in triplicate. 
3.4. Giemsa Staining 
A549 cells were treated by bufalin as describe above and the cells were collected and put on the 
slides. The slides were then rinsed with sterile water and flooded with freshly prepared Giemsa’s stain 
solution (BDH Chemical Ltd) for 5 min. After three times of rinsing in sterile water, the cells were 
examined for morphological changes using a microscopy (Nikon, TMS) with 200× magnification. 
3.5. Flow Cytometry Analysis 
A549 cells were treated by bufalin as describe above and the cells were collected for propidium 
iodide (PI) staining. Briefly, the cells were fixed in 70% ethyl alcohol at 4 °C overnight, then washed 
with PBS and incubated with RNAse (10 μg/mL) at 37 °C for 30 min. Next the cells were incubated 
with PI (final concentration 10 μg/mL) for 30 min in the dark. Samples were analyzed using a 
FACSCalibur flow cytometer within 30 min after the staining. Int. J. Mol. Sci. 2012, 13 2032 
 
 
3.6. Western Blot Analysis 
A549 cells were treated by bufalin as describe above and the cells were collected for Western  
blot analysis. Briefly, the cells were lysed in RIPA buffer for 40 min on the ice. Lysates were collected 
after centrifuging at 12,000 rpm for 20 min at 4 °C. Protein levels were quantified using Lowry 
method. Equivalent amounts of protein (50 μg/lane) were separated by 15% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. The 
membranes were blocked in PBS containing 5% non-fat dry milk (w/v) for 1 h, and then incubated 
with primary antibodies overnight at 4°C. The membranes were then incubated with HRP-conjugated 
secondary antibodies at room temperature for 30 min, and developed using enhanced chemiluminescence 
reagent and exposed to X-ray film. 
3.7. Statistical Analysis 
The data were expressed as the mean ± standard deviation (SD) from experiments performed in 
triplicate. T test was used to identify statistically significant differences between the experimental and 
control groups. The statistical analyses were performed using the SPSS software 13.0 (SPSS Inc., 
Chicago, IL, USA). A value < 0.05 was considered statistical significance. 
4. Conclusions 
Apoptosis is a cell defense mechanism to eliminate malignant cells and plays an important role in 
preventing tumor development. In fact, many anti-cancer drugs function primarily to induce apoptosis 
through regulating apoptosis-associated signaling [13,14]. Bcl-2 family members are known to regulate 
the mitochondrial apoptosis pathway. Anti-apoptotic protein Bcl-2 is located in the mitochondrial outer 
membrane where it inhibits pro-apoptotic molecule Bax to maintain the integrity of the mitochondrial 
outer membrane and prevent the release of Cyt-c and other apoptotic factors, thereby protecting cells 
from apoptosis [15].   
In this study we demonstrate that bufalin treated A549 lung cancer cells exhibited significantly 
higher rates of apoptosis than control treated cells. These results were consistent with the MTT assay 
showing that bufalin inhibited the proliferation of A549 cells in a dose and time dependent manner. 
Therefore, we conclude that the loss of viability of A549 cells treated by bufalin is partly due to the 
induction of apoptotic cell death. 
Notably, we found that bufalin induced apoptosis is associated with the downregulation of Bcl-2 
expression and upregulation of Bax expression in A549 cells, consistent with previous report that 
overexpression of Bcl-2 protein inhibited bufalin-induced apoptosis of leukemia cells [16]. In addition, 
by Giemsa staining we observed cytoplasmic shrinkage, nuclear condensation and the formation of 
apoptotic bodies in A549 cells treated with bufalin. These are characteristic apoptotic morphology, thus 
confirming that bufalin induces the apoptosis of lung cancer cells. Furthermore, our results show that 
the application of caspase-3 inhibitor Z-DEVD-fmk could significantly block the apoptosis of A549 
cells treated with bufalin, indicating that bufalin-induced apoptosis involves the activation of caspase-3.   
Livin is a newly discovered member of inhibitor of apoptosis protein family [17]. The BIR domain 
of livin has a new type of zinc finger structure which could bind Caspase-3 to inhibit its activity, Int. J. Mol. Sci. 2012, 13 2033 
 
 
thereby inhibiting apoptosis [18]. Interestingly, in this study we found that with the duration of bufalin 
treatment, livin expression was significantly inhibited in A549 cells, accompanied by increased 
activation of Caspase-3 and increased apoptosis. A recent study showed that inhibiting livin could 
induce the apoptosis of human bladder cancer cells via a mechanism involving caspase 3 [19]. Based 
on these data we speculate that bufalin downregulates the expression of livin. Consequently, Caspase-3 
gets activated due to the lack of inhibition by livin and apoptosis ensues.   
PI3K/Akt pathway plays critical roles in mammalian cell survival and resistance to apoptosis [20]. 
PI3K/Akt signaling has been shown to be activated in a variety of cancers and activated Akt acts to 
phosphorylate Bad and Caspase-9 or activate NF-κB pathway to promote the resistance of cancer cells 
to apoptosis [21–24]. However, the functional role of PI3K/Akt pathway in bufalin induced cancer cell 
apoptosis remains largely unclear. In the present study we found that bufalin treatment reduced the 
level of phosphorylated Akt when compared to control cells, indicating the inhibition of Akt activation. 
Furthermore, by employing Akt specific inhibitor LY294002 we could demonstrate the synergistic 
effects of bufalin and LY294002 on the induction of apoptosis and regulation of apoptosis related 
proteins in A549 cells. The expression of anti-apoptotic molecules such as Bcl-2 and livin was 
substantially downregulated by pretreatment with LY294002 followed by bufalin treatment of A549 
cells, while the expression of pro-apoptotic protein Bax and the activation of Caspase-3 were 
substantially upregulated. Collectively, these results suggest that bufalin inhibits the activation of 
PI3K/Akt pathway to promote the apoptosis of cancer cells. However, further studies are needed to 
elucidate the mechanism by which bufalin modulates the activation of PI3K/Akt and other signaling 
pathways that are crucial for cancer cell survival and chemoresistance. 
In conclusion, in the present study we demonstrate that bufalin inhibits the proliferation of A549 
cells by inducing the apoptosis in a dose and time dependent manner. Mechanistically, we found that 
bufalin inhibits the activation of PI3K/Akt pathway to regulate the expression of pro-apoptotic and 
anti-apoptotic proteins and promote the activation of Caspase-3, leading to the execution of apoptosis. 
Interestingly, the marked ability of bufalin to synergize with Akt inhibitor to induce cancer cell 
apoptosis suggests that bufalin is a potential regimen for combined chemotherapy to overcome the 
resistance of cancer cells to chemotherapeutics induced apoptosis.   
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